Where: 30 [Show on Floor Plan]
The UK TAVI trial is a multi-centre randomised controlled trial to assess the clinical effectiveness and cost-utility of TAVI, compared with conventional surgical aortic valve replacement (AVR), in patients with severe symptomatic aortic stenosis, who are at intermediate or high operative risk. The primary endpoint is all-cause mortality at one year but patients will be followed for a minimum of 5 years. Secondary outcomes include clinical events, quality of life, functional capacity and cost-utility. The trial involves all of the UK centres that currently perform TAVI and will recruit a total of 808 patients aged 70 years or older. Eligibility is determined by MDT review with no specific numeric risk score threshold. Other unique features of the trial include the use of any CE-marked valve in the TAVI arm and a pragmatic design with minimal exclusion criteria. The trial is funded by the NIHR Health Technology Assessment Programme (Ref: 09/55/63), Sponsored by the University of Leicester and managed by the Surgical Intervention Trials Unit (SITU) in Oxford. ISRCTN: 57819173. If you would like more information please contact Dr William Toff, Chief Investigator (E:; T: 0116 250 2500) or Dr Surjeet Singh, Trial Manager (E:; T: 01865 223476)
Tel: 01865223476
Address: UK TAVI Trial Office
Surgical Intervention Trials Unit (SITU)
University of Oxford
Botnar Research Centre

Staff Attending

Ms Elena Villarreal
Trial Manager


Belfast Waterfront
2 Lanyon Place, Belfast

Hosted By

Society for Cardiothoracic Surgery

The purpose of the Society is to further the interests of all involved in cardiothoracic surgery.
Event Logo Find us on Facebook Follow us on Twitter

Get the App

Get this event information on your mobile by
going to the appstore or google play and search for 'scts'
Eventflo Home
copyright Society for Cardiothoracic Surgery,, Labhoo Ltd 2003-2022